SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump For President

TRUMP Crypto is experiencing intense volatility and social media attention fueled by reports of an exclusive Mar-a-Lago gala invite for top holders, sparking polarized community debates over its legitimacy and the potential for market manipulation. Detractors and supporters alike are actively clashing over the project's ties to political news and the broader grift allegations surrounding the Trump family brand.

Sable Offshore Corp. engages in offshore oil and gas field operations. It focuses on developing the prolific Santa Ynez Unit in federal waters offshore California. The company was founded by James C. Flores on October 16, 2020 and is headquartered in Houston, TX.

Sable Offshore Corp.

Sable Offshore (SOC) is seeing extreme volatility as investors weigh the potential for a massive short squeeze against significant regulatory and legal headwinds. The community is sharply divided between those betting on federal support via the Defense Production Act to bypass California's pipeline restrictions and those concerned about the company's precarious financial position and ongoing environmental litigation.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is facing short-term volatility as traders react to reports of a delayed AI model rollout and broader concerns over aggressive capital expenditures. While community sentiment is heavily polarized between skeptics questioning the stock's long-term growth and bullish investors viewing the dip as a prime accumulation opportunity, the active discussion remains centered on the company's competitive positioning in the AI race and its overall fundamental resilience.

Bittensor is an open-source protocol that powers a decentralized, blockchain-based machine learning network. Machine learning models train collaboratively and are rewarded in TAO according to the informational value they offer the collective. TAO also grants external access, allowing users to extract information from the network while tuning its activities to their needs.  Ultimately, BitTensors vision is to create a pure market for artificial intelligence, an incentivized arena in which consumers and producers of this valuable commodity can interact in a trustless, open and transparent context.  Bittensor enables:  -A novel, optimized strategy for the development and distribution of artificial intelligence technology by leveraging the possibilities of a distributed ledger. Specifically, its facilitation of open access/ownership, decentralized governance, and the ability to harness globally-distributed resources of computing power and innovation within an incentivized framework.  -An open-source repository of machine intelligence, accessible to anyone, anywhere, thus creating the conditions for open and permission-less innovation on a global internet scale.  -Distribution of rewards and network ownership to users in direct proportion to the value they have added.

Bittensor

Bittensor (TAO) is trending as investors aggressively position themselves ahead of its first-ever halving event in December and mounting excitement over recent institutional moves, including Grayscales ETF filing. The community is buzzing with long-term bullish sentiment, actively discussing the potential for decentralized AI to disrupt tech giants while sharing strategies for staking on various high-yield subnets within the ecosystem.

Volatility Shares Trust - 2x Ether ETF

Volatility Shares 2x Ether ETF

The Volatility Shares 2x Ether ETF ($ETHU) is trending as traders heavily leverage the recent volatility in the underlying crypto market, with the community actively debating the pros and cons of using 2x leveraged products to play Ethereum's price swings versus holding the spot asset or other crypto-exposed stocks. Market participants are intensely focused on the ETF's rapid price action and the impact of volatility decay, with many debating optimal entry points during recent price pullbacks and speculating on whether the current market conditions favor a breakout or further consolidation.

BlackRock, Inc. engages in the provision of investment, advisory and risk management solutions. Its products include single-asset and multi-asset portfolios. The company was founded by Laurence Douglas Fink in 1988 and is headquartered in New York, NY.

Blackrock Inc.

BlackRock is currently navigating market volatility driven by significant redemption pressure within its private credit funds, forcing the firm to cap withdrawals for its HPS Corporate Lending Fund. Investors are actively debating whether this signals a broader liquidity crisis in the shadow banking sector or if the firm's robust $14 trillion AUM provides sufficient structural resilience to weather the storm.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

Crypto.com Coin (CRO) is generating significant community buzz driven by institutional partnerships, speculation around upcoming ETF filings, and its role in new prediction market integrations. While some investors remain skeptical of leadership and past price dilution, others are actively accumulating positions in anticipation of a potential bull cycle shift.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending as investors focus on the potential for a curative outcome in its Phase 3 REGAL trial and the recent expansion of its SLS009 pipeline into front-line AML. The community remains intensely focused on the long-awaited 80th event milestone, with active debates surrounding institutional accumulation, warrant activity, and the company's valuation as a prospective buyout candidate.

Ambiq Micro, Inc. engages in the provision of ultra-low power semiconductor solutions designed to address the significant power consumption challenges of general purpose and AI computing. It operates through the following geographical segments: China, Taiwan, Singapore, and Rest of the World. The company was founded by Scott Hanson, Dennis Sylvester, and David Blaauw on January 20, 2010 and is headquartered in Austin, TX.

Ambiq Micro Inc.

Ambiq Micro, Inc.

Ambiq Micro is seeing significant investor attention driven by speculation surrounding a potential partnership with Oura and its specialized ultra-low-power edge AI chip technology. The community is actively debating the company's long-term growth prospects, leadership strategy, and the necessity for a major product announcement to sustain current trading volume and momentum.

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Oruka Therapeutics Inc.

Oruka Therapeutics is drawing significant attention from investors following optimistic clinical data updates and positive analyst sentiment regarding its long-acting psoriasis treatment pipeline. The community is actively debating the company's long-term potential as a competitor in the autoimmune space, balancing excitement over upcoming catalyst readouts with concerns about its historical price volatility and thin trading volume.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Kaleido Biosciences, Inc. is a clinical-stage healthcare company, which engages in the provision of healthcare services. It focuses on leveraging the microbiome organ to treat disease and improve human health. The firm offers microbiome metabolic therapies (MMT), which are designed to modulate the metabolic output and profile of the microbiome by driving the function and composition of the organ's existing microbes. The company was founded by Geoffrey von Maltzahn and Noubar B. Afeyan on January 27, 2015 and is headquartered in Lexington, MA.

KLDO
Kaleido Biosciences, Inc.

Latest KLDO News

KLDOKaleido Biosciences, Inc.

Latest KLDO News

KLDO
Kaleido Biosciences, Inc.